Targeting the molecular basis for tumour hypoxia

Expert Reviews in Molecular Medicine

Volumn 7, Issue 6, 2005, Pages

  Carroll, Veronica A ^a   Ashcroft, Margaret ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; HIF; Targeted cancer therapeutics; Tumour hypoxia

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 17 ALLYLAMINOGELDANAMYCIN; 2 METHOXYESTRADIOL; ADENOVIRUS VECTOR; CARBOPLATIN; COMPLEMENTARY DNA; ENZYME ACTIVATOR; ETOPOSIDE; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PX 478; THIOREDOXIN; TIRAPAZAMINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; PRODRUG; TUMOR PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SENSITIVITY; FIBROSARCOMA; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVIEW; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; CELL HYPOXIA; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RADIATION DOSE; VASCULARIZATION;

ADENOVIRIDAE;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS; PROTEIN STRUCTURE, TERTIARY; RADIATION TOLERANCE;

EID: 31044447666     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399405009117     Document Type: Review

References (144)

1. Harris, A.L. (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2, 3847,
2. Brown, J.M. and Wilson, W.R. (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437-447,
3. Graeber, T.G. et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91,
4. Yu, J.L. et al. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528,
5. Dong, Z. et al. (2001) Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 276, 18702-18709,
6. Schioppa, T. et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-1402,
7. Pennacchietti, S. et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361,
8. Lal, A. et al. (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93, 1337-1343,
9. Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732,
10. Giaccia, A., Siim, B.G. and Johnson, R.S. (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2, 803-811,
11. Greco, O. et al. (2003) How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 197, 312-325,
12. Yeo, E.J., Chun, Y.S. and Park, J.W. (2004) New anticancer strategies targeting HIF-1. Biochem Pharmacol 68, 1061-1069,
13. Wang, G.L. and Semenza, G.L. (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270, 1230-1237,
14. Semenza, G.L. and Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447-5454,
15. Wang, G.L. and Semenza, G.L. (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90, 4304-4308,
16. Semenza, G.L. et al. (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269, 23757-23763,
17. Arany, Z. et al. (1996) An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 93, 12969-12973,
18. Wang, G.L. and Semenza, G.L. (1993) Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268, 21513-21518,
19. Jiang, B.H. et al. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271, 17771-17778,
20. Koshiji, M. et al. (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. Embo J 23, 1949-1956,
21. Jiang, B.H. et al. (1997) Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272, 19253-19260,
22. Pugh, C.W. et al. (1997) Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272, 11205-11214,
23. Huang, L.E. et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95, 7987-7992,
24. Lee, K.H., Park, J.W. and Chun, Y.S. (2004) Non-hypoxic transcriptional activation of the aryl hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha isoform. Nucleic Acids Res 32, 5499-5511,
25. Tian, H., McKnight, S.L. and Russell, D.W. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11, 72-82,
26. Ema, M. et al. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 94, 4273-4278,
27. Wiesener, M.S. et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92, 2260-2268,
28. Gu, Y.Z. et al. (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7, 205-213,
29. Heidbreder, M. et al. (2003) Hypoxia rapidly activates HIF-3alpha mRNA expression. Faseb J 17, 1541-1543,
30. Maynard, M.A. et al. (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278, 11032-11040,
31. Makino, Y. et al. (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550-554,
32. Makino, Y. et al. (2002) Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277, 32405-32408,
33. Jaakkola, P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472,
34. Ivan, M. et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468,
35. Masson, N. et al. (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 20, 5197-5206,
36. Yu, F. et al. (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98, 9630-9635,
37. Maxwell, P.H. et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275,
38. Cockman, M.E. et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275, 25733-25741,
39. Ohh, M. et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2, 423-427,
40. Kamura, T. et al. (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97, 10430-10435,
41. Epstein, A.C. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54,
42. Bruick, R.K. and McKnight, S.L. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340,
43. Berra, E. et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo J 22, 4082-4090,
44. Jeong, J.W. et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111, 709-720,
45. Mahon, P.C., Hirota, K. and Semenza, G.L. (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15, 2675-2686,
46. Lando, D. et al. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861,
47. Lando, D. et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16, 1466-1471,
48. Hewitson, K.S. et al. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277, 26351-26355,
49. Thrash-Bingham, C.A. and Tartof, K.D. (1999) aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 91, 143-151,
50. Uchida, T. et al. (2004) Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 279, 14871-14878,
51. Bardos, J.I. and Ashcroft, M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269,
52. Richards, F.M. (2001) Molecular pathology of von HippelLindau disease and the VHL tumour suppressor gene. Expert Rev Mol Med 2001, 1-27,
53. Wykoff, C.C. et al. (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-6305,
54. Los, M. et al. (1999) Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59, 4440-4445,
55. Jiang, Y. et al. (2003) Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1, 453-462,
56. Wykoff, C.C. et al. (2004) Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90, 1235-1243,
57. Mandriota, S.J. et al. (2002) HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468,
58. Hon, W.C. et al. (2002) Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978,
59. Min, J.H. et al. (2002) Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889,
60. Kondo, K. et al. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246,
61. Maranchie, J.K. et al. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255,
62. Mack, F.A. et al. (2003) Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3, 75-88,
63. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15, 177-182,
64. Li, J. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947,
65. Zundel, W. et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14, 391-396,
66. Blagosklonny, M.V. et al. (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273, 11995-11998,
67. Ravi, R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14, 34-44,
68. An, W.G. et al. (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408,
69. Chen, D. et al. (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278, 13595-13598,
70. Bardos, J.I., Chau, N.M. and Ashcroft, M. (2004) Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol Cell Biol 24, 2905-2914,
71. Zhong, H. et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59, 5830-5835,
72. Turner, K.J. et al. (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62, 2957-2961,
73. Talks, K.L. et al. (2000) The expression and digtribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157, 411-421,
74. Willam, C. et al. (2002) Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc Natl Acad Sci U S A 99, 10423-10428,
75. Maxwell, P.H. et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94, 8104-8109,
76. Carmeliet, P. et al. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490,
77. Ryan, H.E., Lo, J. and Johnson, R.S. (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embo J 17, 3005-3015,
78. Ryan, H.E. et al. (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60, 4010-4015,
79. Hopfl, G. et al. (2002) Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 62, 2962-2970,
80. Flamme, I., Krieg, M. and Plate, K.H. (1998) Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/ HIF-2alpha. Am J Pathol 153, 25-29,
81. Akeno, N. et al. (2001) Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia-inducible factor-2alpha. Endocrinology 142, 939-962,
82. Akeno, N. et al. (2002) Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 143, 420-425,
83. Flamme, I. et al. (1997) HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 63, 51-60,
84. Jain, S. et al. (1998) Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev 73, 117-123,
85. Sowter, H.M. et al. (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63, 6130-6134,
86. Blouw, B. et al. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146,
87. Birner, P. et al. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60, 4693-4696,
88. Burri, P. et al. (2003) Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56, 494-501,
89. Birner, P. et al. (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7, 1661-1668,
90. Sivridis, E. et al. (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95, 1055-1063,
91. Volm, M. and Koomagi, R. (2000) Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20, 1527-1533,
92. Giatromanolaki, A. et al. (2001) Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/ molecular profile of tumours and survival. Br J Cancer 85, 881-890,
93. Aebersold, D.M. et al. (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61, 2911-2916,
94. Koukourakis, M.I. et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53, 1192-1202,
95. Beasley, N.J. et al. (2002) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62, 2493-2497,
96. Bos, R. et al. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93, 309-314,
97. Schindl, M. et al. (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8, 1831-1837,
98. Bos, R. et al. (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581,
99. Koukourakis, M.I. et al. (2001) Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61, 1830-1832,
100. Birner, P. et al. (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92, 165-171,
101. Unruh, A. et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22, 3213-3220,
102. Garcia-Barros, M. et al. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159,
103. Moeller, B.J. et al. (2003) Reactive oxygen species and hypoxia inducible factor-1alpha serve as important vascular stabilizing elements in tumors following radiotherapy. Int J Radiat Oncol Biol Phys 57, S320-S321
104. Moeller, B.J. et al. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441,
105. Workman, P. and Stratford, I.J. (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12, 73-82,
106. Stratford, I.J. and Workman, P. (1998) Bioreductive drugs into the next millennium. Anticancer Drug Des 13, 519-528,
107. Zeman, E.M. et al. (1988) Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12, 209-218,
108. Walton, M.I., Wolf, C.R. and Workman, P. (1992) The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44, 251-259,
109. Evans, J.W. et al. (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58, 2098-2101,
110. Cowen, R.L. et al. (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64, 1396-1402,
111. Dachs, G.U. et al. (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3, 515-520,
112. Binley, K. et al. (2003) Hypoxia-mediated tumour targeting. Gene Ther 10, 540-549,
113. Sun, X. et al. (2001) Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8, 638-645,
114. Sun, X. et al. (2003) Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha. Gene Ther 10, 2081-2089,
115. Hernandez-Alcoceba, R. et al. (2002) New oncolytic adenoviruses with hypoxia-and estrogen receptor-regulated replication. Hum Gene Ther 13, 1737-1750,
116. Post, D.E. and Van Meir, E.G. (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22, 2065-2072,
117. Cuevas, Y. et al. (2003) Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindaudefective renal cell carcinomas. Cancer Res 63, 6877-6884,
118. Mabjeesh, N.J. et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375,
119. Hergovich, A. et al. (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5, 64-70,
120. Welsh S.J. et al. (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2, 235-243,
121. Welsh, S.J. et al. (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62, 5089-5095,
122. Yeo, E.J. et al. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95, 516-525,
123. Welsh, S. et al. (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3, 233-244,
124. Isaacs, J.S. et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277, 29936-29944,
125. Mabjeesh, N.J. et al. (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62, 2478-2482,
126. Banerji, U., Judson, I. and Workman, P. (2003) The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets 3, 385-390,
127. Kamal, A. et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410,
128. Workman, P. (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10, 47-51,
129. Kung, A.L. et al. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6, 1335-1340,
130. Kung, A.L. et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33-43,
131. Rapisarda, A. et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62, 4316-4324,
132. Rapisarda, A. et al. (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64, 1475-1482,
133. Chau, N.M. et al. Identification of novel small molecule inhibitors of HIF-1 that differentially block HIF-1 activity and HIF-1α induction in response to hypoxic stress and growth factors. Cancer Res (in press)
134. Aboagye, E.O. et al. (1997) Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3, 3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res 57, 3314-3318,
135. Seddon, B.M. et al. (2002) Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 8, 2323-2335,
136. Seddon, B.M. et al. (2003) A phase I study of SR4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 9, 5101-5112,
137. Serganova, I. et al. (2004) Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64, 6101-6108,
138. Wen, B. et al. (2004) A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 31, 1530-1538,
139. Barthel, H. et al. (2004) In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 90, 2232-2242,
140. Collingridge, D.R. et al. (2002) The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62, 5912-5919,
141. Richard, D.E. et al. (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274, 32631-32637,
142. Bruick, R.K. (2000) Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A 97, 9082-9087,
143. Sowter, H.M. et al. (2001) HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIF3 and NIX in human tumors. Cancer Res 61, 6669-6673,
144. Lee, M.J. et al. (2004) Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway. Mol Cell Biol 24, 3918-3927,